These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7494940)

  • 1. [The effect of a reduction in plasma cholesterol on the evolution of coronary disease].
    Fernández-Avilés F; García-Morán E
    Rev Esp Cardiol; 1995; 48 Suppl 5():43-51. PubMed ID: 7494940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
    Pitt B; Waters D; Brown WV; van Boven AJ; Schwartz L; Title LM; Eisenberg D; Shurzinske L; McCormick LS
    N Engl J Med; 1999 Jul; 341(2):70-6. PubMed ID: 10395630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of determining serum cholesterol levels in patients with coronary heart disease].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2545-8. PubMed ID: 9555153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease.
    Gould KL
    Am J Med; 1998 Jun; 104(6A):2S-17S. PubMed ID: 9684847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins in the prevention of coronary heart disease.
    Williamson DR; Pharand C
    Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of lowered cholesterol on the course of coronary heart disease. An analysis of the results of controlled, angiographically documented intervention studies].
    Stierle U; Schwabe K; Sheikhzadeh A
    Dtsch Med Wochenschr; 1995 Dec; 120(48):1652-9. PubMed ID: 7493572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
    Waters DD; Azar RR
    Am J Cardiol; 2000 Oct; 86(8B):35J-42J; discussion 42J-43J. PubMed ID: 11081447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid lowering agents. How important are they in secondary prevention of coronary heart disease?
    Colquhoun DM
    Aust Fam Physician; 2002 Jan; 31(1):25-6, 29-30. PubMed ID: 11840884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease].
    Jost S; Lichtlen PR
    Z Kardiol; 1995 Aug; 84(8):577-95. PubMed ID: 7571764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization].
    Castro Beiras A; Vázquez Rodríguez JM; Muñiz J; Calviño R; Vázquez González N; Juane R
    Rev Esp Cardiol; 1995; 48 Suppl 5():23-30. PubMed ID: 7494936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
    Marchioli R; Marfisi RM; Carinci F; Tognoni G
    Arch Intern Med; 1996 Jun; 156(11):1158-72. PubMed ID: 8639010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of coronary heart disease through cholesterol reduction.
    Grundy SM
    Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefit of cholesterol-lowering medications after coronary revascularization: a population study.
    Brophy JM; Brassard P; Bourgault C
    Am Heart J; 2005 Aug; 150(2):282-6. PubMed ID: 16086931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of cholesterol-lowering medications after coronary revascularization.
    Brophy JM; Bourgault C; Brassard P
    CMAJ; 2003 Nov; 169(11):1153-7. PubMed ID: 14638648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.